Business Daily Media

The Times

.

Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial

  • Written by PR Newswire

SYDNEY, July 9, 2025 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) is pleased to announce preliminary results from the first patient in its Phase 1b trial evaluating a combination regimen of Paxalisib, pembrolizumab (Keytruda®), and standard chemotherapy after completing Cycle 1 (21 days) of dosing. The patient, a 61-year-old woman with...

Why self-service is reshaping fleet management for modern businesses

Fleet management today is constrained by fragmented systems and heavy administrative demands. A lot of the work still relies on booking vehicles and...

Fraud Prevention and security crucial as identity crime hits record highs in Australia

In a radically transformed risk landscape where the scale and speed of financial fraud have reached unprecedented levels, Australian businesses ar...

Sectorial ATO Tax Debt Disclosures Rise, Overall Business Credit Demand Flattens and High-Risk SME 'Credit Shopping' hits 8-month peak

Q1 2026 Equifax Business Market Pulse shows low-risk borrowers consolidate demand enquiries while sub-prime entities accelerate shopping activity ...

SME support in Federal Budget falls short of easing business pressures

“The Federal Budget delivered several measures aimed at supporting small businesses, including making the instant asset write-off permanent, exten...

Bunji dog treats to hit Ritchies shelves

Cooee Native Superfoods’ Bunji range of dog kibble and treats is rolling out across Ritchies Supermarkets now, with stock already on shelves in se...

Pre-Budget Expectations

“Australian corporates and SMBs are under pressure. Competition from global players is intensifying, margins are under strain, and technology adop...